摘要
对归脾汤所含各单味药在中药系统药理学数据库与分析平台、医药百科全书数据库、中药分子机制生物信息学分析工具数据库和基于文本挖掘的中医药基因与疾病信息数据库中进行检索,得到各化学成分及其潜在作用靶点合集,进而采用高可信度数据库MetaCore对归脾汤的潜在作用靶点进行疾病富集分析,结果发现归脾汤潜在的治疗疾病包括脑病、胃肠道疾病、营养和代谢疾病、肿瘤与癌症、心血管系统疾病、内分泌系统疾病、免疫系统疾病、药物相关副反应和不良反应、先天性遗传性疾病等。结合该分类,对归脾汤治疗的疾病进行了综述,发现现有归脾汤治疗的疾病研究结果与采用网络药理学预测得到的结果基本一致。说明归脾汤在现代临床上的应用远远超出了其原创应用范围,充分体现了其"异病同治"的功效,但其应用的基础是上述疾病都有心脾气血两虚的临床表现。该文为归脾汤的进一步研究与开发应用提供了借鉴。
The Chinese herbal medicines contained in Guipitang(GPT)were retrieved in the databases,including traditional Chinese medicine systems pharmacology database and analysis platform(TCMSP),encyclopedia of traditional Chinese medicine(ETCM),bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine(BATMAN-TCM),and database for associated traditional Chinese medicine,gene,and disease information using text mining(TCMGeneDIT),and the compounds and their potential targets were obtained. Disease enrichment analysis on the potential targets of GPT was carried out to obtain the diseases potentially treated by GPT using MetaCore. Disease enrichment results showed that the potential diseases treated by GPT included encephalopathy, gastrointestinal diseases, nutritional/metabolic diseases, tumors/cancers,cardiovascular system diseases,endocrine system diseases,immune system diseases,drug-related side effects/adverse reactions,and congenital/hereditary diseases. On these grounds,the diseases treated by GPT were reviewed. The results of the previous research on diseases treated by GPT were consistent with analysis results of network pharmacology. The modern applications of GPT clinically went beyond its original indications,but its applications were based on the clinical manifestation of qi and blood deficiency in the heart and spleen,presenting the characteristic of "same treatment for different diseases". This study is expected to provide a reference for the further research and development of GPT.
作者
陈丽媛
叶田园
齐冬梅
程肖蕊
CHEN Li-yuan;YE Tian-yuan;QI Dong-mei;CHENG Xiao-rui(Shandong University of Traditional Chinese Medicine,Jinan 250355,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2021年第15期219-226,共8页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家自然科学基金面上项目(81974555)。
